21-Gene Assay to Inform Chemotherapy Benefit in Node-Positive Breast Cancer | Zendy

Kevin Kalinsky | Zendy; William E. Barlow | Zendy; Julie R. Gralow | Zendy; Funda MericBernstam | Zendy; Kathy S. Albain | Zendy; Daniel F. Hayes | Zendy; Nancy U. Lin | Zendy; Edith A. Perez | Zendy; Lori J. Goldstein | Zendy; Stephen Chia | Zendy; Sukhbinder DhesyThind | Zendy; Priya Rastogi | Zendy; Emilio Alba | Zendy; Suzette Delaloge | Zendy; Miguel Martín | Zendy; Catherine M. Kelly | Zendy; Manuel RuízBorrego | Zendy; Miguel GilGil | Zendy; Claudia Arce-Salinas | Zendy; Étienne Brain | Zendy; Eun-Sook Lee | Zendy; JeanYves Pierga | Zendy; Begoña Bermejo | Zendy; Manuel Ramos-Vázquez | Zendy; Kyung-Hae Jung | Zendy; JeanMarc Ferrero | Zendy; Anne F. Schott | Zendy; Steven Shak | Zendy; Priyanka Sharma | Zendy; Danika L. Lew | Zendy; Jieling Miao | Zendy; Debasish Tripathy | Zendy; Lajos Pusztai | Zendy; Gabriel N. Hortobágyi | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

21-Gene Assay to Inform Chemotherapy Benefit in Node-Positive Breast Cancer

Author(s) -

Kevin Kalinsky,

William E. Barlow,

Julie R. Gralow,

Funda MericBernstam,

Kathy S. Albain,

Daniel F. Hayes,

Nancy U. Lin,

Edith A. Perez,

Lori J. Goldstein,

Stephen Chia,

Sukhbinder DhesyThind,

Priya Rastogi,

Emilio Alba,

Suzette Delaloge,

Miguel Martín,

Catherine M. Kelly,

Manuel RuízBorrego,

Miguel GilGil,

Claudia Arce-Salinas,

Étienne Brain,

Eun-Sook Lee,

JeanYves Pierga,

Begoña Bermejo,

Manuel Ramos-Vázquez,

Kyung-Hae Jung,

JeanMarc Ferrero,

Anne F. Schott,

Steven Shak,

Priyanka Sharma,

Danika L. Lew,

Jieling Miao,

Debasish Tripathy,

Lajos Pusztai,

Gabriel N. Hortobágyi

Publication year - 2021

Publication title -

new england journal of medicine

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 19.889

H-Index - 1030

eISSN - 1533-4406

pISSN - 0028-4793

DOI - 10.1056/nejmoa2108873

Subject(s) - breast cancer , oncology , chemotherapy , node (physics) , medicine , gene , cancer , cancer research , biology , genetics , engineering , structural engineering

The recurrence score based on the 21-gene breast-cancer assay has been clinically useful in predicting a chemotherapy benefit in hormone-receptor-positive, human epidermal growth factor receptor 2 (HER2)-negative, axillary lymph-node-negative breast cancer. In women with positive lymph-node disease, the role of the recurrence score with respect to predicting a benefit of adjuvant chemotherapy is unclear.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research